REVTORPYK (Gedatolisib) Patent Expiration, LOE Window & CMS Spending

REVTORPYK (Gedatolisib) by Celcuity: FDA Orange Book LOE 2031-07-14, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $10,000 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCelcuity
FDA Application & PathwayN219908 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-07-14
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($10,000 intro WAC)